New schizophrenia drug VV119 enters early human testing
NCT ID NCT06504290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check if the drug is safe and how the body processes it. About 40 participants will take multiple doses to find the right amount for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
-
Beijing Huilongguan Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Xi'an Mental Health Center
RECRUITINGXi’an, Shanxi, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call strengthen families facing schizophrenia?
- Virtual family therapy may tame schizophrenia symptoms — a trial investigates
- Could a Once-Every-Few-Weeks shot replace daily pills for schizophrenia?
- Can a tailored self-management program improve health outcomes for those with serious mental illness?
- PET scans reveal how antipsychotics target key brain receptors in schizophrenia
- Immune clues in schizophrenia: could inflammation subtypes guide treatment?